Health and Artificial Intelligence: Law, Ethics and Society

A 2-day webinar that brings together experts from various stakeholder disciplines for an interdisciplinary discussion on the application and impact of AI in healthcare.

ZOOM Workshop 1

Ethical Considerations and Policy Development

7 December 2020, Monday
7pm – 9pm (Hong Kong Time)

ZOOM Workshop 2

Responsible AI and the Law

8 December 2020, Tuesday
7pm – 9pm (Hong Kong Time)

CHAIRS:

Dr Calvin Ho

Associate Professor of Law & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong

Dr Philip Beh

Principal Clinical Practitioner, Department of Pathology, Li Ka Shing Faculty of Medicine & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong

SPEAKERS:










Ms Alison Hall University of Cambridge
Dr Ping Ji Peking University Clinical Research Institute (Shenzhen)
Prof W. John Kao The University of Hong Kong
Dr Colm McGrath King's College London
Dr María del Rosario Perez World Health Organization
Dr Keren Priyadarshini Microsoft Asia
Dr Jeffrey Skopek University of Cambridge
Prof Ma'n Zawati McGill University



Organised by:

CMEL
The University of Hong Kong Centre for Medical Ethics and Law

CME/CPD Accreditation, Registration & Other Details:

About CMEL

Established in 2012, The Centre for Medical Ethics and Law (CMEL) is a joint effort of two leading faculties, the Li Ka Shing Faculty of Medicine and the Faculty of Law at the University of Hong Kong. Our visions are: to become a focal point for international research excellence in the area of medical ethics and law; to co-ordinate and provide teaching and training to university students and professionals; and to promote and disseminate our expertise to the benefit of the public.

The Centre's objectives are respectively in research, teaching, knowledge exchange and training:

Research:	To produce and disseminate high-quality and cutting edge research in medical ethics and law.
Teaching:	To contribute to the interdisciplinary teaching and learning at the University by providing a forum for the discourse of medical ethics and law.
Knowledge Exchange:	To provide expert training and continuing education to the professionals of both disciplines and to help setting the ethical standard on related issues.
Training:	To promote and disseminate knowledge of medical ethics and law to the public at large and enhance the community's awareness in this regard.

Aligning with the University's vision of 'Internationalisation, Innovation and Interdisciplinarity', the Centre collaborates with institutions, professional bodies and scholars in Hong Kong and internationally in order to pursue these objectives.

About the Workshop

The application of artificial intelligence (AI) in medicine and healthcare has become increasingly commonplace and ubiquitous. This 2-day webinar brings together experts from various stakeholder disciplines for an interdisciplinary discussion on the application and impact of AI in healthcare. The first day of the webinar will consider how ethical concerns over the use of AI have impacted software developers and policymakers. On the second day, the webinar will consider what responsible AI development could mean, and what role the law could have in ensuring this.

Chairs & Speakers

Chairs

Dr Calvin Ho
Associate Professor of Law & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK

Dr Philip Beh
Principal Clinical Practitioner, Department of Pathology, Li Ka Shing Faculty of Medicine & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK

Speakers

Ms Alison Hall
Head of Humanities, PHG Foundation, University of Cambridge, UK

Dr Ping Ji
Deputy Director, Peking University Clinical Research Institute (Shenzhen), China

Prof W. John Kao
Chair Professor of Translational Medical Engineering, Department of Industrial and Manufacturing Systems Engineering and Biomedical Engineering Program, Faculty of Engineering and Li Ka Shing Faculty of Medicine, The University of Hong Kong, HK

Dr Colm McGrath
Lecturer in Tort Law, Dickson Poon School of Law, King's College London, UK

Dr María del Rosario Perez
Scientist, Radiation and Health Unit, Department of Environment, Climate Change and Health (ECH), Division of Healthier Populations (HEP), World Health Organization

Dr Keren Priyadarshini
Regional Business Lead, Worldwide Health, Microsoft Asia

Dr Jeffrey Skopek
University Senior Lecturer in the Faculty of Law & Deputy Director of the Cambridge Centre for Law, Medicine and Life Sciences, University of Cambridge, UK

Prof Ma'n Zawati
Assistant Professor, Executive Director, Centre of Genomics and Policy, McGill University, Canada

Programmes

Health and Artificial Intelligence: Law, Ethics and Society

7 & 8 December 2020
7:00 – 9:00pm (Hong Kong Time)

7 December 2020, 7:00pm - 9:00pm (Hong Kong Time)

Workshop 1: Ethical Considerations and Policy Development

7:00 - 7:10	**Introductory remarks by the Chairs:** **Dr Calvin Ho** Associate Professor of Law & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK **Dr Philip Beh** Principal Clinical Practitioner, Department of Pathology, Li Ka Shing Faculty of Medicine & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK
7:10 - 7:30	**Presentation 1:** **Dr María del Rosario Perez** Scientist, Radiation and Health Unit, Department of Environment, Climate Change and Health (ECH), Division of Healthier Populations (HEP), World Health Organization ***Title: Use of Artificial Intelligence in Chest Imaging***
7:30 - 7:50	**Presentation 2:** **Prof W. John Kao** Chair Professor of Translational Medical Engineering, Department of Industrial and Manufacturing Systems Engineering and Biomedical Engineering Program, Faculty of Engineering and Li Ka Shing Faculty of Medicine, The University of Hong Kong, HK ***Title: AI and Biomedical Technologies: a multi-stakeholders challenge***
7:50 - 8:10	**Presentation 3:** **Dr Ping Ji** Deputy Director, Peking University Clinical Research Institute (Shenzhen), China

	Title: A Qualitative Research of Views on Implementing Ethical Considerations into AI design in Healthcare Field: Shenzhen, China
8:10 - 8:30	**Presentation 4:** **Ms Alison Hall** Head of Humanities, PHG Foundation, University of Cambridge, UK ***Title: Regulating Black Box Medicine: the policy context***
8:30 - 9:00	**Panel discussion and Q & A**

8 December 2020, 7:00pm - 9:00pm (Hong Kong Time)

Workshop 2: Responsible AI and the Law

7:00 - 7:10	**Introductory remarks by the Chairs:** **Dr Calvin Ho** Associate Professor of Law & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK **Dr Philip Beh** Principal Clinical Practitioner, Department of Pathology, Li Ka Shing Faculty of Medicine & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK
7:10 - 7:30	**Presentation 1:** **Dr Keren Priyadarshini** Regional Business Lead, Worldwide Health, Microsoft Asia ***Title: Responsible AI in Healthcare***
7:30 - 7:50	**Presentation 2:** **Dr Jeffrey Skopek** University Senior Lecturer in the Faculty of Law & Deputy Director of the Cambridge Centre for Law, Medicine and Life Sciences, University of Cambridge, UK ***Title: What Difference Does It Make? "Black Box" Medicine and the Law***

7:50 - 8:10	**Presentation 3:** **Dr Colm McGrath** Lecturer in Tort Law, Dickson Poon School of Law, King's College London, UK ***Title: Liability for undisclosed and variant AI treatments***
8:10 - 8:30	**Presentation 4:** **Prof Ma'n Zawati** Assistant Professor, Executive Director, Centre of Genomics and Policy, McGill University, Canada ***Title: Dr App will see you now: Ethical & Legal Challenges of mHealth Apps***
8:30 - 9:00	**Panel discussion and Q & A**

Abstracts

7 December 2020, 7:00pm - 9:00pm (Hong Kong Time)

Workshop 1: Ethical Considerations and Policy Development

PRESENTATION 1

Dr María del Rosario Perez
Scientist, Radiation and Health Unit, Department of Environment, Climate Change and Health (ECH), Division of Healthier Populations (HEP), World Health Organization

Title: Use of Artificial Intelligence in Chest Imaging

Since the COVID-19 outbreak, there has been a strong interest in developing artificial intelligence (AI) software to perform tasks that include the determination of which patients are at greatest risk of complications and which patients can safely receive less intensive care. However, allowing the use of such software that has not undergone rigorous testing during a pandemic may confuse doctors and cause harm to patients. In the United States, the proposed use of AI software to identify COVID-19 patients through chest imaging has been controversial. With focus on a recently published report of the World Health Organization, this presentation discusses the recommended uses of chest imaging in COVID-19, and safeguards that are needed if AI in chest imaging is to be used.

PRESENTATION 2

Prof W. John Kao
Chair Professor of Translational Medical Engineering, Department of Industrial and Manufacturing Systems Engineering and Biomedical Engineering Program, Faculty of Engineering and Li Ka Shing Faculty of Medicine, The University of Hong Kong, HK

Title: AI and Biomedical Technologies: a multi-stakeholders challenge

As a potential game changer, medical AI could have a profound impact on disease prevention, diagnosis, and treatment in addition to outcome improvement and healthcare system management. But how to integrate and translate AI effectively into a myriad of biomedical technologies would require an active collaboration amongst the public sector, research institutions, industry, practitioners, and end-users. Policy reforms without a doubt would play an important role in facilitating this transformation. We will also examine what Hong Kong is doing in building a vibrant biotech ecosystem through multi-stakeholder engagement and capital investment.

PRESENTATION 3

Dr Ping Ji
Deputy Director, Peking University Clinical Research Institute (Shenzhen), China

Title: A Qualitative Research of Views on Implementing Ethical Considerations into AI design in Healthcare Field: Shenzhen, China

Firstly, this talk introduces the status and performance of health AI in China from different aspects in the last five years (2015-2019) based on the health AI index report, which was jointly released by Elsevier and the National Big Health Data Institute at Peking University in 2020. It then gives an introduction on our qualitative research of views on implementing ethical considerations into AI design in healthcare field. Shenzhen has taken actions to support AI R&D technology. It is vital to implementing ethical considerations into health AI R&D. However, existing regulatory frameworks are often inadequate. Aiming to propose appropriate policy recommendations, the Health Commission of Shenzhen and the Peking University Clinical Research Institute (Shenzhen) designed and conducted the present study.

PRESENTATION 4

Ms Alison Hall
Head of Humanities, PHG Foundation, University of Cambridge, UK

Title: Regulating Black Box Medicine: the policy context

This talk explores current applications and near-future opportunities for machine learning in health care and medical research. It then considers the current challenges posed by black box algorithms in meeting the regulatory requirements for interpretability and transparency in EU regulations on medical devices and policy guidance, and evaluates these in relation to these developing AI applications in health. Finally the talk addresses some wider implications for health care professionals, regulators and policy makers.

Abstracts

8 December 2020, 7:00pm - 9:00pm (Hong Kong Time)

Workshop 2: Responsible AI and the Law

PRESENTATION 1

Dr Keren Priyadarshini
Regional Business Lead, Worldwide Health, Microsoft Asia

Title: Responsible AI in Healthcare

It is inevitable that Artificial Intelligence (AI) will become one of the most important technologies of our future. Designing AI to be trustworthy requires creating solutions that reflect ethical principles that are deeply rooted in important and timeless values. Microsoft has defined six principles that we believe should guide the development of AI. Specifically, AI systems should be fair, reliable and safe, private and secure, inclusive, transparent, and accountable. These principles are critical to addressing the societal impacts of AI and building trust as the technology becomes more and more a part of the products and services that people use at work and at home every day. In this session, the speaker will describe these principles in details and share Microsoft best practice as well as its view on AI policy and ethics consideration for the healthcare industry.

PRESENTATION 2

Dr Jeffrey Skopek
University Senior Lecturer in the Faculty of Law & Deputy Director of the Cambridge Centre for Law, Medicine and Life Sciences, University of Cambridge, UK

Title: What Difference Does It Make? "Black Box" Medicine and the Law

This talk explores whether and how the much-discussed opacity of machine learning algorithms might be legally relevant in healthcare. After sketching the various areas of law in which opacity is thought to be legally relevant, I challenge this premise of difference, arguing that machine learning systems are more similar to existing medical technologies and practices than is often recognised. I then apply this difference-sceptical approach to an area of law that has attracted considerable interest in the health AI context: the law of clinical negligence. Finding little support for the claim that machine learning will necessitate a transformation of the existing legal framework, I conclude that if such a transformation does come to pass, it will be due to policy choices rather than technological imperatives.

PRESENTATION 3

Dr Colm McGrath
Lecturer in Tort Law, Dickson Poon School of Law, King's College London, UK

Title: Liability for undisclosed and variant AI treatments

Here we consider two questions rooted in the private law analysis of AI and healthcare: 1) Is a healthcare practitioner or institution liable, as a matter of malpractice, to disclose that they will be using AI in the course of the patient's treatment; 2) Does a healthcare practitioner or institution owe a duty to offer treatment using AI over conventional means where this is available or to disclose that an AI- based variant course of treatment exists. Through investigating these questions we contribute to the broader mapping of the private law response to technological innovation and the relationship between AI, healthcare and liability.

PRESENTATION 4

Prof Ma'n Zawati
Assistant Professor, Executive Director of the Centre of Genomics and Policy, McGill University, Canada

Title: Dr App Will See You Now: Ethical & Legal Challenges of mHealth Apps

Wearable and mobile devices that record and organize personal health information are becoming increasingly ubiquitous. Many of us own devices capable of tracking our activities, counting our steps, estimating our caloric intake, measuring the quality of our sleep, and even recording our heart rate. And while this kind of information promises to empower consumers, enabling them to better understand their health and fitness, such technologies also raise certain legal and ethical questions about data management, privacy, and how we make decisions about our health.

Biographies

CHAIRS

Dr Calvin Ho
Associate Professor of Law & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK



Dr Calvin Ho is Associate Professor with the Faculty of Law, and Co-Director of the Centre for Medical Ethics, at the University of Hong Kong. His research is primarily on the governance of health- and biomedical technologies, including human genome editing, human pluripotent stem cell research, and health technologies based on Artificial Intelligence and data analytics. He is an Ethics Board member of Médecins Sans Frontières (Doctors Without Borders), and a member of the Access to COVID-19 Tools (ACT) Accelerator Ethics Working Group of the World Health Organization.

Dr Philip Beh
Principal Clinical Practitioner, Department of Pathology, Li Ka Shing Faculty of Medicine & Co-Director, Centre for Medical Ethics and Law, The University of Hong Kong, HK

Dr Beh is Co-Director of CMEL since its inception. He is a forensic pathologist by training and has been teaching medical ethics at the faculty of medicine for over twenty years.

Biographies

SPEAKERS

Ms Alison Hall
Head of Humanities, PHG Foundation, University of Cambridge, UK

Alison is Head of Humanities at the PHG Foundation, a health policy think tank which is part of University of Cambridge. Her research focuses on the regulation and governance of genomic data for clinical care and research and the challenges and opportunities associated with delivering personalised healthcare.

Recent work has focused on the impact of EU Regulations on data protection and in vitro diagnostic devices on the implementation of automated processing and artificial intelligence in healthcare. This includes a Wellcome Trust funded project *Black Box Medicine and Transparency* an iterative evaluation of philosophical and legal requirements for transparency in machine learning for healthcare and research, and a project on the *General Data Protection Regulation and genomic data* funded by the UK Information Commissioner's Office. These projects build on earlier work on medical devices regulation (*Algorithms as medical devices*), and on other aspects of the algorithm regulation *Regulating algorithms in healthcare*. Other research interests include the impact of novel genomic technologies on the future of healthcare (*Polygenic scores, risk and cardiovascular disease*).

She is a longstanding member of the Global Alliance for Genomics in Health's regulatory and ethics work stream, chair of the Ethics and Policy Committee of the British Society for Genetic Medicine, a member of METADAC (a UK Data Access Committee) and a member of an NHS research ethics committee. Alison has professional qualifications in law and nursing and a master's qualification in healthcare ethics.

Dr Ping Ji
Deputy Director, Peking University Clinical Research Institute (Shenzhen), China

Dr Ping Ji began her clinical research career as medical writer and monitor for industry in China after obtaining her PhD in 2006 at Cardiff University, UK. She developed her interests in medical research ethical review and human subjects protection since 2010. She took the role as director of Quality Assurance Office in Peking University Human Research Protection Program by 2016. Since 2016, she moved to Shenzhen for building clinical research support and supervision platforms for education & training, technological support, ethical review, and policy development with the support from the local health authority. Together with her colleagues, her team has made great achievements on developing regional clinical research infrastructure.

Prof W. John Kao
Chair Professor of Translational Medical Engineering, Department of Industrial and Manufacturing Systems Engineering and Biomedical Engineering Program, Faculty of Engineering and Li Ka Shing Faculty of Medicine, The University of Hong Kong, HK

Professor W. John Kao is the Chair Professor of Translational Medical Engineering at the University of Hong Kong (HKU). Before joining HKU, he was Vilas Distinguished Achievement Professor of Pharmacy, Surgery, and Biomedical Engineering at the University of Wisconsin – Madison. Professor Kao studied biomedical engineering at the Johns Hopkins University (BS), Case Western Reserve University (MS) and macromolecular science and engineering (PhD) also at Case Western. He subsequently worked at the California Institute of Technology (Caltech) and Eidgenössische Technische Hochschule (ETH, Swiss Federal Institute of Technology in Zürich) prior to joining the faculty at UW-Madison for 18 years. While on leave, he currently heads the Biomedical Technologies Cluster at the HK Science and Technology Park.

Professor Kao's research focuses on developing therapeutics for cancer and wound healing. He is an elected fellow of the American Institute of Medical and Biological Engineering, the Hong Kong Institutions of Engineers, and the International Union of Societies for Biomaterials Science and Engineering, where he also has served as the Secretary for the College of Fellows. He is on several editorial boards and his extensive involvement with industry, regulatory and policy bureaus has enabled him to build a successful record in translating enabling technologies to the market. His research has been funded by the National Institutes of Health, the National Science Foundation, and other federal and private agencies. He has published extensively in top journals and more than 170 other publications including abstracts, book chapters, and patents. He has mentored more than 60 undergraduate, graduate, post-graduate students, and clinician scientists from around the world.

Dr Colm McGrath
Lecturer in Tort Law, Dickson Poon School of Law, King's College London, UK

Dr Colm McGrath is a Lecturer in Tort Law at the Dickson Poon School of Law at King's College London. Previously, he was the WYNG Research Fellow in Medical Law and Ethics at Trinity Hall, Cambridge and a member of the University of Cambridge's Centre for Law, Medicine and Life Sciences. Colm is joint General Editor of the long-running Journal of Professional Negligence and the Book Review Editor for the Journal of European Tort Law. He is a Fellow of the European Centre for Tort and Insurance Law and a member of the International Advisory Board of the Rivista Responsabilita Medica. His monograph *The Development of Medical Liability in Germany 1800-1945* was selected by jury as one of the "2019 Legal Books of the Year" in the Neue Juristische Wochenschrift.

Dr María del Rosario Perez
Scientist, Radiation and Health Unit, Department of Environment, Climate Change and Health (ECH), Division of Healthier Populations (HEP), World Health Organization

Dr María del Rosario Pérez joined the Radiation and Environmental Health team as a Scientist in April 2007. Her main responsibility at WHO is the technical coordination of the WHO Global Initiative on Radiation Safety in Health Care Settings. She also contributes to the development of evidence-based guides, norms and standards on ionizing radiation and environmental health and to activities on preparedness and response in radiation emergencies.

Dr Pérez received her M.D. in 1980 from the School of Medicine of Buenos Aires University, Argentina. She specialized on Radiation Oncology, obtained her diploma in Radiation Protection and Nuclear Safety from the School of Engineering of Buenos Aires University, and completed her formation in Epidemiology in the National Academy of Medicine. Her professional activity has been related with radiation protection and human health. She contributed to the implementation of programs of education and training in Latin America, where she has actively promoted regional cooperation on medical and public health response in emergencies.

She was the head of the Radiopathology Laboratory at the Nuclear Regulatory Authority, director of the REMPAN Liaison Institution in Argentina, alternate representative of Argentina at United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), consultant of UNSCEAR on Effects of Ionizing Radiation of the Immune System and member of the Advisory Council in Radioisotopes and Radiations. She was member of international expert teams involved in the preparedness and response in radiation emergencies.

She coordinated research projects on the effects of ionizing radiation on the immune system, foetal brain, and dermal endothelial cells. Her research interests also included diagnosis and treatment of radiation injuries, bioindicators of radiation exposure and radio-epidemiology. Dr Pérez has contributed to more than 80 technical papers and presentations on these areas.

Dr Keren Priyadarshini
Regional Business Lead, Worldwide Health, Microsoft Asia

As the Regional Business Lead of Healthcare in Microsoft Asia, Dr. Keren Priyadarshini leads the company's healthcare business segment across 17 markets in Asia Pacific.

Keren is responsible for driving and implementing Microsoft's healthcare initiatives across the region as well as developing solution offerings and strategies that meet the needs of healthcare and life science customers. She also plays a leading role in establishing thought leadership by defining and articulating the company's vision for the future of healthcare and sharing how Microsoft technologies and partner solutions are making it a reality.

Keren is passionate about empowering providers, payors, and life science companies with the right technology to enable better patient outcomes at lower costs. Improving the quality of healthcare through digital transformation; enabling wider access to healthcare as life expectancy increases, and keeping rising costs in check are issues that keep her awake at night.

Her desire being to create a world of 'Intelligent Healthcare' through AI and the cloud, to unlock biological insight and break data from silos for a truly personal understanding of human health and in turn, enable better access to care, lower costs and improved outcomes.

Keren moved to Singapore almost 15 years ago and has been instrumental in establishing the Asia Pacific business for multinational healthcare companies such as GfK and Truven Health. Before joining Microsoft, Keren was the Asia Pacific Vice President of Sales for Truven Health Analytics, part of the IBM Watson Health, where she pioneered the adoption of Watson in the region.

Born in Chennai, India, Keren graduated as a Fellow from the Indian Institute of Management (IIM-A), Ahmedabad, where she completed her Doctorate in Business Management.

Keren is married with two children. In her spare time, she works with less privileged kids and helps them realize their potential through innovative methods. She is also a foster parent with the Ministry of Social and Family Development (MSF) in Singapore and has fostered several children over the last eight years.

Dr Jeffrey Skopek
University Senior Lecturer in the Faculty of Law & Deputy Director of the Cambridge Centre for Law, Medicine and Life Sciences, University of Cambridge, UK

Jeff Skopek is a University Senior Lecturer in the Faculty of Law of the University of Cambridge, the Deputy Director of the Cambridge Centre for Law, Medicine and Life Sciences, and a Fellow of Hughes Hall. His work explores the normative and conceptual foundations of medical law, focusing in particular on controversies about the harms and benefits that are generated by medical treatment, health care systems, and biomedical research. He recently completed several projects on privacy and anonymity, and he is currently the PI on a Wellcome Trust funded project on liability for harms caused by the use of AI in health care. Outside of academia, he has served on the Health and Social Care Advisory Panel for the UK government's Centre for Digital Ethics and Innovation and on Astra Zeneca's Animal Welfare Ethics Review Board. Before becoming an academic, he served as a law clerk to the Chief Judge of the United States Court of Appeals for the First Circuit. He has been awarded Fulbright, Gates, and Truman Scholarships and holds a J.D. from Harvard Law School, a Ph.D. and M.Phil. in the History and Philosophy of Science from the University of Cambridge, and an A.B. in History from Stanford University.

Prof Ma'n Zawati
Assistant Professor, Executive Director, Centre of Genomics and Policy, McGill University, Canada

Ma'n H. Zawati (LL.B., LL.M., Ph.D. (DCL)) is an Assistant Professor at McGill University's Faculty of Medicine and the Executive Director of the Centre of Genomics and Policy in the Department of Human Genetics. He is also an Associate Member of McGill's Biomedical Ethics Unit. His research concentrates on the legal, ethical and policy dimensions of health research and clinical care, with a special focus on biobanking, data sharing, professional liability, and the use of novel technologies (e.g. mhealth apps, WGS, WES) in both the clinical and research settings. His work is interdisciplinary, drawing together perspectives from law, ethics, bioinformatics, genomics, and policy. He's also a frequent presenter on a variety of the most critical and topical issues in healthcare and the biosciences. He has appeared at 100+ international conferences, symposia, meetings, and has shared his expertise with universities, research ethics boards and law firms. Prof. Zawati has published 13 book chapters and 45+ peer reviewed articles in leading publications such as *Nature Reviews Genetics*, the *Canadian Medical Association Journal*, the *Journal of Law and the Biosciences*, the *Journal of Medical Genetics*, and the *McGill Journal of Law and Health*. In 2015, he was awarded the Queen Elizabeth II Diamond Jubilee Scholarship (stay at Oxford University) and was named a Royal Society of Canada Delegate for the IAP Young Scientists of the Year international symposium. In 2014, the Young Bar Association of Montreal named him as one of its Lawyers of the Year.

Health and Artificial Intelligence: Law, Ethics and Society

7 & 8 December 2020

Organized by:

CMEL

The University of Hong Kong
Centre for Medical Ethics and Law

Centre for Medical Ethics & Law, The University of Hong Kong

Address: Rm 921, 9/F, Cheng Yu Tung Tower,
Centennial Campus, The University of Hong Kong
Email: cmel@hku.hk
Website: https://www.cmel.hku.hk
Facebook: https://www.facebook.com/pg/CMELHKU
Twitter: https://twitter.com/HKU_CMEL
Tel: (852) 3917 1845
Fax: (852) 2549 8495